Ceres decreases second quarter losses
Ceres Inc. narrowed its losses but revenues were still low during the second quarter. The Thousand Oaks-based ag-biotech company said net losses decreased from $8.01 million in the second quarter of 2015 to $1 million in the second quarter of 2016, the company reported April 14. Losses also fell from $1.34 per share last year Read More →
Amgen to pay dividend of $1 per share
Thousand Oaks-based biotech giant Amgen announced it will pay a second quarter dividend of $1 per share. Amgen increased its first quarter dividend to $1 per share from 79 cents on Dec. 15, which Amgen paid to shareholders during each quarter last year. Amgen will pay the dividend on June 8 to shareholders who own Read More →
Amgen revenues up 8 percent in 2015
Despite increased competition from biosimilars and blockbuster mergers by its rivals, Amgen revenues rose 8 percent to $21.67 billion in 2015 from $20.06 billion in 2014. Thousand Oaks-based biotech giant Amgen released its fourth-quarter earnings after markets closed on Jan. 28. Quarterly revenues were also up 4 percent to $5.54 billion in 2015 from $5.33 Read More →
Ceres awarded patent in Australia for trait that increases crop yields
Thousand Oaks-based Ceres Inc., an ag-biotech company, was awarded a patent in Australia for a trait that allows growers to increase yields without increasing crop inputs like fertilizer. The patent extends intellectual property protection to the Australian market of a key gene that Ceres has licensed to a multinational crop developer. It covers uses of Read More →
Ceres still raising money despite losses
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Shire buying Conejo Valley’s Baxalta
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen suffers setback as patent office refuses to review competitor’s drug
The U.S. Patent and Trademark Office handed Amgen a potential setback Jan. 14 when it declined to review two patent expiration dates on a competitor’s drug. In June, Thousand Oaks-based biotech giant Amgen asked the agency to review two formulation patents for Humira, made by Chicago-based competitor AbbVie, arguing that the patents should not have Read More →
